Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1

Conditions

Sarcoma, Synovial 3Mesothelioma 3Sarcoma 2Rhabdoid Tumor 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Solid Tumor 1Mesothelioma, Malignant 1Hepatic Impairment 1Hematologic Neoplasms 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 10Nivolumab 5Granulocyte Colony-Stimulating Factor 4atezolizumab 3Ipilimumab 3Ifosfamide 3Etoposide 3tislelizumab 2sargramostim 2durvalumab 2Thiotepa 2Paclitaxel 2Mesna 2Melphalan 2Filgrastim 2Docetaxel 2Cyclophosphamide 2Carboplatin 2Busulfan 2tazemetostat 1spartalizumab 1regorafenib 1pegylated granulocyte colony-stimulating factor 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1etoposide phosphate 1epacadostat 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × tazemetostat × Other solid neoplasm × Clear all
NCT03874455 2024-03-22

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Ipsen

No longer available
GenitourinaryOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Renal Cell, Chondrosarcoma, Sarcoma, Sarcoma, Synovial, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡